Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by
targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B …

Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …

Background Ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for the
treatment of relapsing forms of multiple sclerosis (RMS), binds to a unique conformational …

Despite the growing popularity of subcutaneous (SC) administration for monoclonal
antibodies (mAbs), there remains a limited understanding of the significance of mAb …

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3
cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b …

The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …

Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …

Background RTX is used off-label in several neurological inflammatory diseases in adults
children patients. We conducted a study to assess indications and safety of rituximab (RTX) …

Objective Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …

UCL 16:9 PP Plain - MID RED Page 1 Mathematical Modelling of CD19+ B Cell
Reconstitution in Children After Insult to the Immune System PAGE Lewis Sheiner Student …